Defilade Capital Management
Defilade Capital Management reported 30 stocks worth $599M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PFE (7.3%), LLY (6.7%) and BMRN (6.0%). Compared with Q2 2026, the fund opened new positions in GILD, AXSM and AMGN, added to ORIC, ASND and COGT, trimmed PFE, LLY and BMRN and sold out of PTCT, BAX and INSM.
Latest filing: what Defilade Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PFE Pfizer Inc | $43.5M | 7.3% | 1.5M | −247K (−14%) | 4 of 4 | |
| 2 | ![]() LLY Eli Lilly & Co | $40.2M | 6.7% | 35K | −4,312 (−11%) | 4 of 4 | |
| 3 | ![]() BMRN Biomarin Pharmaceutical Inc | $36.1M | 6.0% | 602K | −80K (−12%) | 2 of 4 | |
| 4 | ![]() GILD Gilead Sciences Inc | $33.8M | 5.6% | 227K | New position | 1 of 4 | |
| 5 | ![]() AXSM Axsome Therapeutics Inc | $32.3M | 5.4% | 175K | New position | 1 of 4 | |
| 6 | ![]() AMGN Amgen Inc | $31.2M | 5.2% | 74K | New position | 1 of 4 | |
| 7 | ![]() ORIC Oric Pharmaceuticals Inc | $30.6M | 5.1% | 2.3M | +1.2M (+117%) | 3 of 4 | |
| 8 | ![]() ASND Ascendis Pharma A/s | $29.4M | 4.9% | 129K | +34K (+36%) | 2 of 4 | |
| 9 | ![]() ISRG Intuitive Surgical Inc | $29.2M | 4.9% | 72K | New position | 3 of 4 | |
| 10 | ![]() SYK Stryker Corporation | $22.5M | 3.8% | 82K | New position | 1 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() PTCT Ptc Therapeutics Inc | $35.4M | 434K |
![]() BAX Baxter Intl Inc | $31.1M | 1.5M |
![]() INSM Insmed Inc | $30M | 282K |
![]() ZBH Zimmer Biomet Hldgs Inc | $27.3M | 317K |
![]() PODD Insulet Corp | $26.9M | 177K |
🔒 Free account: see all 17.
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Defilade Capital Management 13F FAQ
What does Defilade Capital Management own?
Defilade Capital Management reported 30 stocks worth $599M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PFE (7.3%), LLY (6.7%) and BMRN (6.0%). The table above lists every position in the filing (the top 10 without an account).
What did Defilade Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 8 new positions, 9 added to, 11 trimmed and 17 sold out. New positions include GILD, AXSM and AMGN. It sold all of PTCT, BAX and INSM.
When will Defilade Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Defilade Capital Management's portfolio worth?
The Q3 2026 filing reports $599M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.





















